Continuous Production of Five Active Pharmaceutical Ingredients in Flexible Plug-and-Play Modules: A Demonstration Campaign

Luke Rogers(Massachusetts Institute of Technology), N.E.B. Briggs(Massachusetts Institute of Technology), Ramona Achermann(Massachusetts Institute of Technology), Andrea Adamo(Massachusetts Institute of Technology), Mohammad Azad(Massachusetts Institute of Technology), David Brancazio(Massachusetts Institute of Technology), Gerard Capellades(Massachusetts Institute of Technology), Gregory Hammersmith(Massachusetts Institute of Technology), Travis Hart(Massachusetts Institute of Technology), Joseph Imbrogno(Massachusetts Institute of Technology), Liam Kelly(Massachusetts Institute of Technology), Guohua Liang(Massachusetts Institute of Technology), Clémence Neurohr(Massachusetts Institute of Technology), Kersten Rapp(Massachusetts Institute of Technology), M. Grace Russell(Massachusetts Institute of Technology), Carter Salz(Massachusetts Institute of Technology), Dale A. Thomas(Massachusetts Institute of Technology), Lukas Weimann(Massachusetts Institute of Technology), Timothy F. Jamison(Massachusetts Institute of Technology), Allan S. Myerson(Massachusetts Institute of Technology), Klavs F. Jensen(Massachusetts Institute of Technology)
Organic Process Research & Development
June 24, 2020
Cited by 81

Abstract

Traditional pharmaceutical manufacturing is based on a complex supply chain that is vulnerable to spikes in demand and interruptions. Continuous pharmaceutical production in compact modules is a potential solution that allows for drug manufacturing when and where it is needed with significantly shorter lead times. As part of the Pharmacy on Demand (PoD) initiative, we demonstrate the potential for end-to-end manufacturing of multiple drug substances in reconfigurable devices, under common industrial constraints, and within a challenging manufacturing time frame. A new set of refrigerator-sized modules was constructed for the synthesis, isolation, and formulation of several drugs, with focus on achieving high manufacturing throughputs, and allowing for the production of pharmaceutical tablets. Their operation is demonstrated with the synthesis and formulation of USP-compliant tablets of diazepam, diphenhydramine hydrochloride, and ciprofloxacin hydrochloride, as well as liquid formulations of lidocaine hydrochloride and atropine sulfate.


Related Papers

No related papers found

Powered by citation graph analysis